Morgan Stanley raised the firm’s price target on AbbVie (ABBV) to $231 from $218 and keeps an Overweight rating on the shares following a “beat and raise” Q3 report. 2025 commentary “continues to build confidence in the growth outlook,” says the analyst, who raised estimates mainly on higher Rinvoq/Skyrizi expectations, partially offset by lower aesthetics and Humira sales forecasts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie price target raised to $226 from $215 at Citi
- AbbVie Reports Solid Q3 2024 Financial Performance
- Alphabet, AMD report Q3 earnings beats: Morning Buzz
- AbbVie: Shift in Humira sales volume to biosimilar ‘playing out as anticipated’
- ABBV Earnings: AbbVie Reports Strong Q3 Results, Raises Outlook